Wang, Yinghong http://orcid.org/0000-0002-5148-6130
Wiesnoski, Diana H.
Helmink, Beth A.
Gopalakrishnan, Vancheswaran
Choi, Kati
DuPont, Hebert L.
Jiang, Zhi-Dong
Abu-Sbeih, Hamzah http://orcid.org/0000-0003-3577-6741
Sanchez, Christopher A.
Chang, Chia-Chi
Parra, Edwin R.
Francisco-Cruz, Alejandro
Raju, Gottumukkala S.
Stroehlein, John R.
Campbell, Matthew T. http://orcid.org/0000-0003-1915-4491
Gao, Jianjun
Subudhi, Sumit K. http://orcid.org/0000-0001-5208-7732
Maru, Dipen M.
Blando, Jorge M.
Lazar, Alexander J.
Allison, James P.
Sharma, Padmanee
Tetzlaff, Michael T.
Wargo, Jennifer A.
Jenq, Robert R.
Article History
Received: 27 February 2018
Accepted: 27 September 2018
First Online: 12 November 2018
Change Date: 27 November 2018
Change Type: Correction
Change Details: In the version of this article originally published, an author was missing from the author list. Alexander J. Lazar should have been included between Jorge M. Blando and James P. Allison. The author has been added to the list, and the author contributions section has been updated to include Alexander J. Lazar’s contribution to the study. The error has been corrected in the print, PDF and HTML versions of the manuscript.
Competing interests
: J.A.W. and V.G. are inventors on a US patent application (PCT/US17/53,717) submitted by The University of Texas MD Anderson Cancer Center that covers methods to enhance checkpoint blockade therapy by the microbiome., J.A.W. is a paid speaker for Imedex, Dava Oncology, Omniprex, Illumina, Gilead, MedImmune and Bristol Meyers Squibb. J.A.W. is a consultant / advisory board member for Roche-Genentech, Novartis, Astra-Zeneca, Glaxo Smith Klein, Bristol Meyers Squibb, Merck, and Microbiome DX. J.A.W. also receives clinical trial support from Glaxo Smith Klein, Roche-Genentech, Bristol Meyers Squibb, and Novartis. V.G. is a consultant at Microbiome DX, and ExpertConnect. R.R.J. is on the scientific advisory board for Seres Therapeutics, Inc., has consulted for Ziopharm Oncology and Microbiome Dx, and holds patents licensed to Seres Therapeutics, Inc. M.T.T. serves on the advisory board for Novartis, Seattle Genetics, and Myriad Genetics. J.A.W., P.S., and J.P.A. are members of the Parker Institute for Cancer Immunotherapy at MD Anderson Cancer Center. P.S. is a consultant for Constellation, Kite Pharma, Neon, BioAtla, Pieris Pharmaceuticals, Oncolytics Biotech, Merck, BioMx, Forty-Seven, Polaris, Apricity, Marker Therapeutics, Codiak, Jounce Therapeutics, and is also a stockholder from Jounce Therapeutics, Neon, BioAtla, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, and Kite Pharma. J.P.A. is a stockholder for Jounce Therapeutics, Neon, BioAtla, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, and Kite Pharma. J.P.A. is also a consultant for Jounce Therapeutics, Neon, Amgen, Forty-Seven, Apricity, Polaris, Marker Therapeutics, Codiak, BioAlta LLC, and Tvardi Therapeutics. The other authors declare no competing interests.